Murillo de Oliveira Antunes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Murillo de Oliveira Antunes has a total of 232 co-authors. Here are the top co-authors by number of shared publications:
- Charles Mady
Universidade de São Paulo, Brasil
10 shared publications - Fábio Fernandes
Instituto do Coração do Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo
6 shared publications - Edmundo Arteaga-Fernández
Universidade de São Paulo, Brasil
5 shared publications - Geraldo Lorenzi-Filho
Universidade de São Paulo
5 shared publications - José Eduardo Krieger
Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo
5 shared publications - Carlos Alberto Pastore
Department of Cardiology, University of Sao Paulo, Sao Paulo, Brazil
4 shared publications
Latest Publications
- Open Access
- 5 October 2026
- Published by Oxford University Press (OUP) in European Stroke Journal
- Vol. 11 (10)
Intensive blood-pressure control for the prevention of major cardiovascular events in stroke patients: rationale and design of the OPTIMAL-STROKE trial
Background: In high cardiovascular risk populations without prior stroke, intensive blood pressure (BP) lowering confers greater reductions in cardiovascular events than standard targets. However, optimal BP targets in patients with ischaemic stroke (IS) or TIA remain uncertain. The primary objective of the OPTIMAL-STROKE trial is to assess whether an intensive systolic BP (SBP) target (SBP < 120 mmHg) reduces major cardiovascular events in patients with previous IS or TIA compared to a standard SBP target (SBP < 140 mmHg). Study design: OPTIMAL-STROKE is a multicentre, randomised, controlled, open-label clinical trial with blinded and independent assessment of clinical outcomes and intention-to-treat primary analysis. Patients with a history of IS or TIA and high BP (SBP of 130–180 mmHg), clinically stable for at least 48 h prior to trial inclusion, are centrally randomised with concealed allocation in a 1:1 ratio to either an intensive BP control strategy targeting a SBP < 120 mmHg or a standard control strategy targeting a SBP < 140 mmHg. A total of 495 primary outcome events, 4368 patients enrolled. Study endpoints: The primary outcome is the first occurrence of a composite outcome of major cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, hospitalisation for unstable angina or hospitalisation for heart failure). Summary: OPTIMAL-STROKE will be the first adequately powered trial of intensive BP control in the prevention of major cardiovascular events in patients with a history of IS or TIA. Trial registration: The trial is registered at ClinicalTrials.gov (NCT04036409).
- 5 October 2026
- Published by Oxford University Press (OUP) in European Stroke Journal
- Vol. 11 (10)
Open AccessIntensive blood-pressure control for the prevention of major cardiovascular events in stroke patients: rationale and design of the OPTIMAL-STROKE trial
Background: In high cardiovascular risk populations without prior stroke, intensive blood pressure (BP) lowering confers greater reductions in cardiovascular events than standard targets. However, optimal BP targets in patients with ischaemic stroke (IS) or TIA remain uncertain. The primary objective of the OPTIMAL-STROKE trial is to assess whether an intensive systolic BP (SBP) target (SBP < 120 mmHg) reduces major cardiovascular events in patients with previous IS or TIA compared to a standard SBP target (SBP < 140 mmHg). Study design: OPTIMAL-STROKE is a multicentre, randomised, controlled, open-label clinical trial with blinded and independent assessment of clinical outcomes and intention-to-treat primary analysis. Patients with a history of IS or TIA and high BP (SBP of 130–180 mmHg), clinically stable for at least 48 h prior to trial inclusion, are centrally randomised with concealed allocation in a 1:1 ratio to either an intensive BP control strategy targeting a SBP < 120 mmHg or a standard control strategy targeting a SBP < 140 mmHg. A total of 495 primary outcome events, 4368 patients enrolled. Study endpoints: The primary outcome is the first occurrence of a composite outcome of major cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, hospitalisation for unstable angina or hospitalisation for heart failure). Summary: OPTIMAL-STROKE will be the first adequately powered trial of intensive BP control in the prevention of major cardiovascular events in patients with a history of IS or TIA. Trial registration: The trial is registered at ClinicalTrials.gov (NCT04036409).
- Open Access
- 15 May 2026
- Vol. 123 (2) , e20260119
The Thickness That Deceives: The Role of Imaging, Biopsy, and Genetics in the Evaluation of Ventricular Hypertrophy.
- 15 May 2026
- Vol. 123 (2) , e20260119
Open AccessThe Thickness That Deceives: The Role of Imaging, Biopsy, and Genetics in the Evaluation of Ventricular Hypertrophy.
- Open Access
- 1 January 2026
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 123 (2)
The Thickness That Deceives: The Role of Imaging, Biopsy, and Genetics in the Evaluation of Ventricular Hypertrophy
- 1 January 2026
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 123 (2)
Open AccessThe Thickness That Deceives: The Role of Imaging, Biopsy, and Genetics in the Evaluation of Ventricular Hypertrophy
- Open Access
- 1 January 2026
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 123 (2)
A Espessura que Engana: O Papel da Imagem, da Biópsia e da Genética na Avaliação da Hipertrofia Ventricular
- 1 January 2026
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 123 (2)
Open AccessA Espessura que Engana: O Papel da Imagem, da Biópsia e da Genética na Avaliação da Hipertrofia Ventricular
- Open Access
- 1 January 2025
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 122 (2) , e20240535
Doença de Fabry e seus Diferentes Fenótipos
Resumo A Doença de Fabry (DF) é uma condição genética ligada ao cromossomo X, causada por variantes no gene GLA, que resultam na deficiência da enzima α-galactosidase A e no acúmulo de globotriaosilceramida (Gb3) em tecidos como o coração, rins e sistema nervoso. Este estudo relata uma série de casos envolvendo pacientes diagnosticados com DF, destacando a diversidade fenotípica da doença, que pode ser confundida com outras condições cardiológicas. A avaliação genética, aliada à dosagem de biomarcadores e à atividade enzimática da α-galactosidase, quando bem indicadas, é essencial para o diagnóstico preciso. O diagnóstico precoce da DF é fundamental para a implementação de tratamentos que retardem a sua progressão, além de evitar complicações graves, reforçando a necessidade de maior conscientização entre os cardiologistas sobre essa condição.
- 1 January 2025
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 122 (2) , e20240535
Open AccessDoença de Fabry e seus Diferentes Fenótipos
Resumo A Doença de Fabry (DF) é uma condição genética ligada ao cromossomo X, causada por variantes no gene GLA, que resultam na deficiência da enzima α-galactosidase A e no acúmulo de globotriaosilceramida (Gb3) em tecidos como o coração, rins e sistema nervoso. Este estudo relata uma série de casos envolvendo pacientes diagnosticados com DF, destacando a diversidade fenotípica da doença, que pode ser confundida com outras condições cardiológicas. A avaliação genética, aliada à dosagem de biomarcadores e à atividade enzimática da α-galactosidase, quando bem indicadas, é essencial para o diagnóstico preciso. O diagnóstico precoce da DF é fundamental para a implementação de tratamentos que retardem a sua progressão, além de evitar complicações graves, reforçando a necessidade de maior conscientização entre os cardiologistas sobre essa condição.
- Open Access
- 1 January 2025
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 122 (2)
Fabry Disease and Its Different Phenotypes
Fabry disease (FD) is an X-linked genetic condition caused by variants in the GLA gene causing enzyme α-galactosidase A deficiency and accumulation of globotriaosylceramide (Gb3) in tissues such as the heart, kidneys, and the nervous system. This study reports a case series of patients with FD, highlighting the phenotypic diversity of the disease, which can be confused with other cardiological conditions. When properly indicated, genetic evaluation, combined with biomarker dosage and α-galactosidase enzymatic activity, is key for an accurate diagnosis. Early diagnosis of FD is fundamental for initiating treatments that can slow disease progression and prevent serious complications, reinforcing the need for greater awareness about this condition among cardiologists.
- 1 January 2025
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 122 (2)
Open AccessFabry Disease and Its Different Phenotypes
Fabry disease (FD) is an X-linked genetic condition caused by variants in the GLA gene causing enzyme α-galactosidase A deficiency and accumulation of globotriaosylceramide (Gb3) in tissues such as the heart, kidneys, and the nervous system. This study reports a case series of patients with FD, highlighting the phenotypic diversity of the disease, which can be confused with other cardiological conditions. When properly indicated, genetic evaluation, combined with biomarker dosage and α-galactosidase enzymatic activity, is key for an accurate diagnosis. Early diagnosis of FD is fundamental for initiating treatments that can slow disease progression and prevent serious complications, reinforcing the need for greater awareness about this condition among cardiologists.
- Open Access
- 17 December 2024
- Published by Ubiquity Press, Ltd. in Global Heart
- Vol. 19 (1) , 94
Validation of ACC/AHA and ESC Sudden Cardiac Death Risk Guidelines in Diverse Hypertrophic Cardiomyopathy Cohort: Stratification HCM Study
Sudden cardiac death (SCD) is a major concern in patients with hypertrophic cardiomyopathy (HCM). The American College of Cardiology/American Heart Association (ACC/AHA) and the European Society of Cardiology (ESC) have different guidelines for SCD risk stratification. Their comparative performance in diverse populations remains uncertain. Evaluate the performance of the 2020 ACC/AHA and 2014 ESC guidelines for SCD stratification in a Brazilian cohort with HCM. This retrospective cohort study included patients diagnosed with HCM who were followed in a dedicated clinic at a tertiary hospital in Brazil. The primary outcome was SCD, aborted cardiac arrest due to ventricular fibrillation (VF), sustained ventricular tachycardia (SVT), an episode of VF or SVT, or appropriate ICD therapy. Risk prediction models were assessed using the C-index. A total of 187 patients were included, with a mean follow-up of 8.3 years. The 2020 ACC/AHA guidelines classified 106 (56%) patients as high-risk for SCD, while the 2014 ESC guidelines identified 54 (29%). The primary outcome occurred in 12% of the high-risk group identified by the ACC/AHA guidelines and 13% of the high-risk group identified by the ESC guidelines. Both guidelines showed low discriminatory power for SCD risk in this Brazilian cohort, with AUC values of 0.634 and 0.581 for the ACC/AHA and ESC guidelines, respectively. The 2020 ACC/AHA and 2014 ESC guidelines have limitations in predicting SCD events and defining ICD indications in Brazilian HCM patients. Further studies are needed to refine risk stratification and optimize SCD prevention in this population.
- 17 December 2024
- Published by Ubiquity Press, Ltd. in Global Heart
- Vol. 19 (1) , 94
Open AccessValidation of ACC/AHA and ESC Sudden Cardiac Death Risk Guidelines in Diverse Hypertrophic Cardiomyopathy Cohort: Stratification HCM Study
Sudden cardiac death (SCD) is a major concern in patients with hypertrophic cardiomyopathy (HCM). The American College of Cardiology/American Heart Association (ACC/AHA) and the European Society of Cardiology (ESC) have different guidelines for SCD risk stratification. Their comparative performance in diverse populations remains uncertain. Evaluate the performance of the 2020 ACC/AHA and 2014 ESC guidelines for SCD stratification in a Brazilian cohort with HCM. This retrospective cohort study included patients diagnosed with HCM who were followed in a dedicated clinic at a tertiary hospital in Brazil. The primary outcome was SCD, aborted cardiac arrest due to ventricular fibrillation (VF), sustained ventricular tachycardia (SVT), an episode of VF or SVT, or appropriate ICD therapy. Risk prediction models were assessed using the C-index. A total of 187 patients were included, with a mean follow-up of 8.3 years. The 2020 ACC/AHA guidelines classified 106 (56%) patients as high-risk for SCD, while the 2014 ESC guidelines identified 54 (29%). The primary outcome occurred in 12% of the high-risk group identified by the ACC/AHA guidelines and 13% of the high-risk group identified by the ESC guidelines. Both guidelines showed low discriminatory power for SCD risk in this Brazilian cohort, with AUC values of 0.634 and 0.581 for the ACC/AHA and ESC guidelines, respectively. The 2020 ACC/AHA and 2014 ESC guidelines have limitations in predicting SCD events and defining ICD indications in Brazilian HCM patients. Further studies are needed to refine risk stratification and optimize SCD prevention in this population.
- 2 July 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 150 (1) , 82-85
Effect of Apixaban on Clinical Outcomes in Outpatients With COVID-19: The APOLLO Randomized Clinical Trial
- 2 July 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 150 (1) , 82-85
Effect of Apixaban on Clinical Outcomes in Outpatients With COVID-19: The APOLLO Randomized Clinical Trial
- Open Access
- 4 March 2024
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 121 (1) , e20230834
Zebras Também Existem!
A doença de Fabry (DF) é uma doença rara de armazenamento lisossômico hereditário ligado ao cromossomo X, causado pela atividade deficiente da enzima alfa-galactosidase A que leva ao acúmulo de globotriasilceramida (Gb3) nos tecidos afetados, incluindo o coração, cérebro e rins. Na DF a lesão cardíaca inicia-se cedo progredindo de forma subclínica antes do aparecimento de sintomas e geralmente se manifesta como hipertrofia ventricular esquerda simulando cardiomiopatia hipertrofia (CMH). Estudos recente demonstraram uma prevalência de DF até 5% em pacientes
- 4 March 2024
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 121 (1) , e20230834
Open AccessZebras Também Existem!
A doença de Fabry (DF) é uma doença rara de armazenamento lisossômico hereditário ligado ao cromossomo X, causado pela atividade deficiente da enzima alfa-galactosidase A que leva ao acúmulo de globotriasilceramida (Gb3) nos tecidos afetados, incluindo o coração, cérebro e rins. Na DF a lesão cardíaca inicia-se cedo progredindo de forma subclínica antes do aparecimento de sintomas e geralmente se manifesta como hipertrofia ventricular esquerda simulando cardiomiopatia hipertrofia (CMH). Estudos recente demonstraram uma prevalência de DF até 5% em pacientes